Age-Related Progression of Microvascular Dysfunction in Cystic Fibrosis: New Detection Ways and Clinical Outcomes

M Kreslová1, A Sýkorová, R Bittenglová

  • 1Department of Pediatrics, Charles University in Prague, Faculty of Medicine in Pilsen, Faculty Hospital, Pilsen, Czech Republic. kreslovam@fnplzen.cz.

Physiological Research
|October 30, 2021
PubMed

Insights

Cardiovascular risk in cystic fibrosis (CF) is linked to worsening vascular function over time. Early biomarker changes in children suggest future endothelial dysfunction, impacting disease severity.

Area of Science:

  • Cardiovascular Science
  • Pediatric Pulmonology
  • Vascular Biology

Background:

  • Altered vascular functions are implicated in chronic disease pathogenesis and severity.
  • Cardiovascular risk in pediatric cystic fibrosis (CF) requires further understanding.

Purpose of the Study:

  • To analyze vascular disease risk in CF patients.
  • To investigate changes in vascular function over time in CF and control groups.

Main Methods:

  • Prospective enrollment of 22 CF subjects and 22 healthy controls.
  • Assessment of endothelial function using Reactive Hyperemia Index (RHI).
  • Measurement of endothelial dysfunction biomarkers: ADMA, hsCRP, VCAM-1, and E-selectin.

Main Results:

  • CF young adults exhibited significantly lower RHI values.
  • CF patients showed significantly increased hsCRP, E-selectin, and VCAM-1 since childhood.
  • Findings indicate progressive microvascular dysfunction with age in CF patients.

Conclusions:

  • Microvascular dysfunction progresses with age in CF patients, increasing cardiovascular disease risk.
  • Elevated biomarkers in CF children suggest potential endothelial dysfunction development over time.
  • Early detection and management of endothelial dysfunction are crucial for CF patient support.